Senescence in premalignant tumours
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Oncogene-induced senescence is a cellular response that may be crucial for protection against cancer development, but its investigation has so far been restricted to cultured cells that have been manipulated to overexpress an oncogene. Here we analyse tumours initiated by an endogenous oncogene, ras, and show that senescent cells exist in premalignant tumours but not in malignant ones. Senescence is therefore a defining feature of premalignant tumours that could prove valuable in the diagnosis and prognosis of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
From Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor (2008) · cites this paper as [16]
In the citing paper
“In addition to identifying known cell-cycle regulators, these studies identified DCR2 as a common marker of senescence (Collado et al., 2005), later shown to characterize other types of senescence.”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Collado et al., 2005
In the citing paper
“OIS or senescence induced by loss of a tumor suppressor was verified in vivo in human and murine preneoplastic lesions (Collado et al., 2005; Gorgoulis and Halazonetis, 2010; Kuilman and Peeper, 2009) and primary or treated neoplasias (Haugstetter et al., 2010).”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Collado et al., 2005
In the citing paper
“Studies in various mouse models, supported by correlative evidence from human- derived tissue samples, have underscored the tumour- suppressive role of OIS 81,120-123 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [122]
In the citing paper
“This type of oncogene-induced senescence (OIS) is frequently observed in premalignant and benign tumour tissues [37 -39] but not in advanced malignant tumours, where cancer cells have already bypassed senescence.”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [38]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Self-citationRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
p19ARF links the tumour suppressor p53 to Ras
Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 615
Self-citationTumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 571
Self-citation
Cited by
Items 501–600 of 1,005
Bahrami, A., Bo, S., Jamialahmadi, T., & Sahebkar, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101024 · Cited by 72
Khalil, R., Diab‐Assaf, M., & Lemaître, J.-M. (2023) · Cells · doi:10.3390/cells12060915 · Cited by 74
“However, when the limb had fully recovered, these senescent cells disappeared [46].”
BackgroundFunctional Role of Cellular Senescence in Biliary Injury
Meng, L., Quezada, M., Levine, P., Han, Y., McDaniel, K., Zhou, T., Lin, E., Glaser, S., Meng, F., Francis, H., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.10.027 · Cited by 68
Cdc6 as a novel target in cancer: Oncogenic potential, senescence and subcellular localisation
Lim, N., & Townsend, P. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32900 · Cited by 73
Tateishi, K., Ohta, M., Kanai, F., Guleng, B., Tanaka, Y., Asaoka, Y., Tada, M., Seto, M., Jazag, A., Lianjie, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0449 · Cited by 69
“However, oncogenic cells bypass this process due to the lack of oncogene-induced senescence effectors, such as p16 or p53 (1), and establish malignant transformation.”
BackgroundMechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Satoh, Y., Ishii, N., & Aoki, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0927-t · Cited by 69
“This phenomenon has been documented in cells harboring variants of BRAF (31), KRAS (32), and EGFR (33), and involves p53 or RB pathway activation (34).”
BackgroundIwagami, Y., Huang, C., Olsen, M. J., Thomas, J., Jang, G., Kim, M., Lin, Q., Carlson, R. I., Wagner, C. E., Dong, X., et al. (2015) · Hepatology · doi:10.1002/hep.28411 · Cited by 73
“Recent studies have disclosed a close correlation of senescence with premalignant stages of tumorigenesis,((40)) but in the fully transformed malignant phenotype, this regulatory mechanism is lost.((40)) Accumulating evidence supports a key role for cellular senescence as a barrier to tumor progression.”
BackgroundZhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 81
Sahu, S. K., Reddy, P., Lu, J. Y., Shao, Y., Wang, C., Tsuji, M., Núñez‐Delicado, E., Esteban, C. R., & Belmonte, J. C. I. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg1777 · Cited by 78
RAS Transformation Requires CUX1-Dependent Repair of Oxidative DNA Damage
Ramdzan, Z. M., Vadnais, C., Pal, R., Vandal, G., Cadieux, C., Leduy, L., Davoudi, S., Hulea, L., Yao, L., Karnezis, A. N., et al. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001807 · Cited by 62
“A Kras knock-in was shown to induce senescence in lung adenomas and in pancreatic intraductal neoplasias [82].”
Backgroundp16INK4a‐induced senescence is disabled by melanoma‐associated mutations
Haferkamp, S., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00422.x · Cited by 59
“…senescence is disabled by melanoma-associated mutations Sebastian Haferkamp, Therese M. Becker, Lyndee L. Scurr, Richard F. Kefford and Helen Rizos Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia”
BackgroundOncogenes and senescence: breaking down in the fast lane
Hemann, M. T., & Narita, M. (2007) · Genes & Development · doi:10.1101/gad.1514207 · Cited by 63
Jost, T., Heinzerling, L., Fietkau, R., Hecht, M., & Distel, L. V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740002 · Cited by 66
Zeppernick, F. A., Ardighieri, L., Hannibal, C. G., VANG, R. S., Junge, J., Kjær, S. K., Zhang, R., Kurman, R. J., & Shih, I. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000313 · Cited by 69
Burns, T. F., Dobromilskaya, I., Murphy, S. C., Gajula, R. P., Thiyagarajan, S., Chatley, S. N. H., Aziz, K., Cho, Y.-J., Tran, P. T., & Rudin, C. M. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0456 · Cited by 61
Autophagy-mediated degradation of nuclear envelope proteins during oncogene-induced senescence
Lenain, C., Gusyatiner, O., Douma, S., van den Broek, B., & Peeper, D. S. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv124 · Cited by 61
“Several studies have demonstrated that this phenomenon, which was initially identified and characterized in vitro, acts as a robust tumor suppressor mechanism in vivo (2-5).”
BackgroundTherapy-induced polyploidization and senescence: Coincidence or interconnection?
Sikora, E., Czarnecka‐Herok, J., Bojko, A., & Sunderland, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.015 · Cited by 68
Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression
Zhang, Z., Rosen, D. G., Yao, J. L., Huang, J., & Liu, J. (2006) · Modern Pathology · doi:10.1038/modpathol.3800655 · Cited by 73
“14 p1ARF, p1INK4b, p1INK4a, and DCR2 have been recently identified as senescence markers”
BackgroundThe epigenomic interface between genome and environment in common complex diseases
Bell, C. G., & Beck, S. (2010) · Briefings in Functional Genomics · doi:10.1093/bfgp/elq026 · Cited by 67
“This may be due to a number of events including the passage of premalignant genomes towards senescence before they acquire the ability to escape this [39], an adaptation to hypoxia, which is experienced very early in tumour development [40–42], or increased cellular plasticity and acquirement of the ability for lineag…”
Cellular senescence bypass screen identifies new putative tumor suppressor genes
Martínez-Leal, J. F., Fominaya, J. M., Cascón, A., Guijarro, M. V., Blanco‐Aparicio, C., LLeonart, M. E., Castro, M. E., y Cajal, S. R., Robledo, M., Beach, D., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210846 · Cited by 75
“Although the process of senescence occurs both in vitro and in vivo (Dimri et al., 1995; Schmitt et al., 2002; Shay and Roninson, 2004; Braig et al., 2005; Collado et al., 2005; Michaloglou et al., 2005), the transition to the senescent phenotype is commonly studied in culture where a cell population can be grown and…”
BackgroundSelf-citationCellular senescence: mechanisms and relevance to cancer and aging
Yamauchi, S., & Takahashi, A. (2024) · The Journal of Biochemistry · doi:10.1093/jb/mvae079 · Cited by 69
“Senescence markers, including p16 INK4a , are detected in premalignant lesions but not in malignant tumors (19) .”
Helmbold, H., Komm, N., Deppert, W., & Bohn, W. (2009) · Oncogene · doi:10.1038/onc.2009.222 · Cited by 68
“Importance of Rb2/p130 in tumor suppression and cancer therapy Senescence can prevent oncogenic transformation and therefore acts as a barrier in early tumor development (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005).”
BackgroundMAIER, A. B., WESTENDORP, R. G. J., & VAN HEEMST, D. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1395.035 · Cited by 61
Limited Role of Murine ATM in Oncogene-Induced Senescence and p53-Dependent Tumor Suppression
Efeyan, A., Murga, M., Martinez-Pastor, B., Ortega-Molina, A., Soria, R., Collado, M., Fernandez-Capetillo, O., & Serrano, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005475 · Cited by 58
“Again, as in the case of MEFs, we could not detect evidence of persistent DNA damage signaling in the K-RasV12-driven adenomas, which were invariably senescent as shown in [37] (Fig.”
BackgroundSelf-citationEpigenetic silencing of 14-3-3sigma in cancer
Lodygin, D., & Hermeking, H. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.03.008 · Cited by 69
Oxidative Stress and Cell Senescence Process
Faraonio, R. (2022) · Antioxidants · doi:10.3390/antiox11091718 · Cited by 73
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Timofeev, O. N., Giron, P., Lawo, S., Pichler, M., & Noeparast, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00554-5 · Cited by 75
Liu, M., Gu, L., Zhang, Y., Li, Y., Zhang, L., Xin, Y., Wang, Y., & Xu, Z. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217025 · Cited by 70
MicroRNAs as Cancer Players: Potential Clinical and Biological Effects
Bandrés, E., Agirre, X., Ramírez, N., Zárate, R., & García‐Foncillas, J. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0544 · Cited by 65
“Oncogenic activation of RAS in primary cells induced cellular senescence and loss of P53 allows cancer cells to overcome this response and continue proliferating (Collado et al. , 2005).”
Prostatic preneoplasia and beyond
Joshua, A. M., Evans, A., van der Kwast, T., Zieleńska, M., Meeker, A. K., Chinnaiyan, A. M., & Squire, J. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.001 · Cited by 82
“[260,261].”
Activation of the aryl hydrocarbon receptor by TCDD inhibits senescence: A tumor promoting event?
Ray, S. S., & Swanson, H. I. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.022 · Cited by 62
“[30] Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al.”
BackgroundMethodThe role of TGFBI in mesothelioma and breast cancer: association with tumor suppression
Li, B., Wen, G., Zhao, Y., Tong, J., & Hei, T. K. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-239 · Cited by 67
“Senescence is an aging state during which cells lose the ability to divide, which is often controlled by some oncogenes and tumor suppressors [24-26].”
BackgroundLatini, F. R. M., Hemerly, J. P., Oler, G., Riggins, G. J., & Cerutti, J. M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0079 · Cited by 62
“2003, Collado et al .”
Regulation of Senescence in Cancer and Aging
Kong, Y., Cui, H., Ramkumar, C., & Zhang, H. (2011) · Journal of Aging Research · doi:10.4061/2011/963172 · Cited by 69
“In mouse tumor models with oncogenic Ras, senescent cells are found in premalignant lesions in lung [61], spleen [144], breast [145], and pancreas [146].”
BackgroundThe therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Regulation of self‐renewal in normal and cancer stem cells
Falzacappa, M. V. V., Ronchini, C., Reavie, L. B., & Pelicci, P. G. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08727.x · Cited by 72
Coleman, P. R., Hahn, C. N., Grimshaw, M. J., Lü, Y., Li, X., Brautigan, P. J., Beck, K., Stocker, R., Vadas, M. A., & Gamble, J. R. (2010) · Blood · doi:10.1182/blood-2009-11-252700 · Cited by 67
“Cellular senescence together with apoptosis is viewed as a major pathway to control cell proliferation and suppress tumourigenesis.(1,2) Recent evidence suggests that the senescence program may have a broader role, as an active mechanism to limit disease progression.”
BackgroundPIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311
Yang, J. H., Liu, K., Yang, J. H., Jin, B., Chen, H., Zhan, X., Li, Z., Wang, L., Shen, X., Li, M., et al. (2017) · Oncogene · doi:10.1038/onc.2017.96 · Cited by 63
Narkhede, A. A., Crenshaw, J. H., Crossman, D. K., Shevde, L. A., & Rao, S. S. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.02.039 · Cited by 66
p16INK4a modulates p53 in primary human mammary epithelial cells.
Zhang, J., Pickering, C. R., Holst, C. R., Gauthier, M. L., & Tlsty, T. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1594 · Cited by 60
“Senescence markers were identified in premalignant lesions, which supports the hypothesis that bypass of senescence may be an early event in carcinogenesis ( 26 ).”
BackgroundCorpet, A., & Stucki, M. (2014) · Chromosoma · doi:10.1007/s00412-014-0469-6 · Cited by 63
“They stain positive for the tumor suppressor PML and have been implicated in the onset of OIS (Bernardi and Pandolfi 2007; Lallemand-Breitenbach and de The 2010).”
BackgroundInfluentialRyan, B. M., Robles, A. I., McClary, A. C., Haznadar, M., Bowman, E. D., Pine, S. R., Brown, D. W., Ma, K., Shiraishi, K., Kohno, T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2101 · Cited by 62
“Senescence is a potent tumor suppressive mechanism (45-47) and might explain why expression of CXCR2 is decreased in lung cancer.”
Reddy, J. P., Peddibhotla, S., Bu, W., Zhao, J., Haricharan, S., Du, Y. N., Podsypanina, K., Rosen, J. M., Donehower, L. A., & Li, Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910665107 · Cited by 64
“2), although senescence has been considered an important barrier to carcinogenesis (12, 13, 45–47), and has been suggested to be lost in progression to breast carcinomas and other malignancies (18, 32, 48).”
BackgroundING1a expression increases during replicative senescence and induces a senescent phenotype
Soliman, M. A., Berardi, P., Pastyryeva, S., Bonnefin, P., Feng, X., Colina, A. R., Young, D., & Riabowol, K. T. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00427.x · Cited by 77
Androgen receptor levels are upregulated by Akt in prostate cancer
Ha, S., Ruoff, R., Kahoud, N., Franke, T. F., & Logan, S. K. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0204 · Cited by 65
“…levels of p27/kip1, resulting in cellular senescence (Majumder et al. 2008); this is consistent with reports that cellular senescence is often seen in early or pre-invasive stages of cancer (Chen et al. 2005, Collado et al. 2005, Michaloglou et al. 2005).”
Nek4 Regulates Entry into Replicative Senescence and the Response to DNA Damage in Human Fibroblasts
Nguyen, C. L., Possemato, R., Bauerlein, E. L., Xie, A., Scully, R., & Hahn, W. C. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00436-12 · Cited by 68
Horiguchi, M., Koyanagi, S., Okamoto, A., Suzuki, S. O., Matsunaga, N., & Ohdo, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1891 · Cited by 58
“In contrast to reversible cell cycle arrest, cellular senescence is defined by irreversible loss of proliferative potential, acquisition of characteristic morphology, and expression of specific biomarkers, such as SA β-gal (8,17).”
BackgroundZou, M., Baitei, E. Y., Al‐Rijjal, R. A., Parhar, R. S., Al-Mohanna, F. A., Kimura, S., Pritchard, C. A., BinEssa, H. A., Alzahrani, A. S., Al‐Khalaf, H. H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.253 · Cited by 63
DNA Replication Stalling Attenuates Tyrosine Kinase Signaling to Suppress S Phase Progression
Shields, B. J., Hauser, C., Bukczynska, P. E., Court, N. W., & Tiganis, T. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.003 · Cited by 64
Carbonneau, C. L., Despars, G., Rojas-Sutterlin, S., Fortin, A., Le, O., Hoang, T., & Beauséjour, C. M. (2012) · Blood · doi:10.1182/blood-2011-06-361626 · Cited by 59
Tissue-specific p19 Arf regulation dictates the response to oncogenic K-ras
Young, N. P., & Jacks, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004796107 · Cited by 59
MicroRNAs are critical regulators of senescence and aging in mesenchymal stem cells
Potter, M. L., Hill, W., Isales, C. M., Hamrick, M. W., & Fulzele, S. (2020) · Bone · doi:10.1016/j.bone.2020.115679 · Cited by 63
USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity
Li, J., Wang, Y., Luo, Y., Liu, Y., Yi, Y., Li, J., Pan, Y., Li, W., You, W., Hu, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35557-y · Cited by 65
Irreversible cell cycle exit associated with senescence is mediated by constitutive MYC degradation
Afifi, M. M., Crncec, A., Cornwell, J. A., Cataisson, C., Paul, D., Ghorab, L. M., Hernandez, M. O., Wong, M., Kedei, N., & Cappell, S. D. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113079 · Cited by 69
“54 We expanded on this model with live, single-cell experiments in vitro and human tissue immunostaining.”
DNA damage responses in skin biology—Implications in tumor prevention and aging acceleration
Nakanishi, M., Niida, H., Murakami, H., & Shimada, M. (2009) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.09.001 · Cited by 62
“Emerging results reveals that the phenomenon of cellular senescence represents a physiological tumor suppressive mechanism with a potential correlation to tissue aging [68,69], showing a significant increase in the number of senescent cells in tissues from old-aged persons.”
BackgroundMartínez‐Romero, C., Rooman, I., Skoudy, A., Guerra, C. E., Molero, X., González-Castro, A. M., Iglesias, M., Lobato, T., Bosch, A., Barbacid, M., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2585 · Cited by 63
“Our results suggest that Ring1B up-regulation in PanIN2/3 and PDAC could be involved in bypassing one or more barriers to neoplasia, such as the oncogene-induced senescence [47].”
BackgroundSelf-citationQian, Y., Jung, Y.-S., & Chen, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203185109 · Cited by 61
“DEC1 is defined as a senescence marker because it is up-regulated in premalignant tumors (15).”
BackgroundMartin, A., & Sarkar, A. (2017) · Nanotoxicology · doi:10.1080/17435390.2017.1366574 · Cited by 67
“Depending on the level of DNA damage, cells may become irreversibly dormant; senescent or be led into cellular death or turn malignant (Collado et al. 2005; Braig et al. 2005).”
BackgroundTargeting normal and cancer senescent cells as a strategy of senotherapy
Sikora, E., Bielak-Zmijewska, A., & Mosieniak, G. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100941 · Cited by 56
Using Mice to Examine p53 Functions in Cancer, Aging, and Longevity
Donehower, L. A. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001081 · Cited by 55
“…in the lung and pancreas, early stage premalignant lung adenomas and pancreatic intraductal neoplasias showed high levels of several senescence markers, whereas malignant lung adenocarcinoma and pancreatic ductal adenocarcinomas displayed a comparative absence of such markers (Collado et al. 2005).”
BackgroundOlivares‐Illana, V., & Fåhræus, R. (2010) · Oncogene · doi:10.1038/onc.2010.266 · Cited by 65
“Animal models have suggested that preventing senescence can promote more malignant tumour progression and cells carrying characteristics of senescent cells can be found in pre-malignant samples that are lost as the state of transformation of the tumour cells increases (Braig et al., 2005; Collado et al., 2005; Dankort…”
BackgroundZHANG, D.-F., Shimizu, T., Araki, N., Hirota, T., Yoshie, M., Ogawa, K., Nakagata, N., Takeya, M., & Saya, H. (2008) · Oncogene · doi:10.1038/onc.2008.76 · Cited by 62
Osteopontin Stimulates Preneoplastic Cellular Proliferation Through Activation of the MAPK Pathway
Luo, X., Ruhland, M. K., Pazolli, E., Lind, A. C., & Stewart, S. A. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0472 · Cited by 59
Chen, J., Chen, K., Xiao, F., Dai, H., Yang, J. W., Li-ming, W., Wang, X., Jian-guo, Z., & He, Y. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.026 · Cited by 63
“DcR2 has been considered a hallmark of cell senescence.(18,19) A previous study found that DcR2 was highly expressed in oncogene-induced premalignant tumors, similar to other”
BackgroundResultTanaka, Y., & Takahashi, A. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa109 · Cited by 64
Thrombospondin-1 mediates oncogenic Ras–induced senescence in premalignant lung tumors
Baek, K.-H., Bhang, D., Zaslavsky, A., Wang, L.-C., Vachani, A., Kim, C. F., Albelda, S. M., Evan, G. I., & Ryeom, S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67465 · Cited by 57
“It is proposed that the protracted latency in adenocarcinoma development is due, at least in part, to Kras -induced senescence stalling progression in premalignant adenomas: only when clones evolve that are refractory to oncogenic Ras –induced senescence can tumors progress toward malignancy (14).”
InfluentialE3 ubiquitin ligase Skp2 as an attractive target in cancer therapy
Hao, Z., & Huang, S. (2015) · Frontiers in bioscience · doi:10.2741/4320 · Cited by 59
NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2
Donninger, H., Calvisi, D. F., Barnoud, T., Clark, J., Schmidt, M., Vos, M. D., & Clark, G. J. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201408087 · Cited by 60
“The detection of Rasinduced senescence in multiple cell culture systems (Serrano et al., 1997; Ferbeyre et al., 2002), in vivo mouse models (Collado et al., 2005; Morton et al., 2010; Kennedy et al., 2011), human rasopathies (Courtois-Cox et al., 2006), and premalignant activated Ras-containing…”
BackgroundMa, K., Xu, Q., Wang, S., Zhang, W., Liu, M., Liang, S., Zhu, H., & Xu, N. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.045 · Cited by 62
PIM‐1 modulates cellular senescence and links IL‐6 signaling to heterochromatin formation
Jin, B., Wang, Y., Wu, C. L., Liu, K. Y., Chen, H., & Mao, Z. B. (2014) · Aging Cell · doi:10.1111/acel.12249 · Cited by 54
“Senescence is an important tumor suppression mechanism that restrains the proliferation of cells harboring activated oncogenes (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005).”
BackgroundSuda, K., Tomizawa, K., Osada, H., Maehara, Y., Yatabe, Y., Sekido, Y., & Mitsudomi, T. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.007 · Cited by 59
Senescence and tumor suppression
Hinds, P., & Pietruska, J. (2017) · F1000Research · doi:10.12688/f1000research.11671.1 · Cited by 57
Cellular senescence or stemness: hypoxia flips the coin
Otero-Albiol, D., & Carnero, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02035-0 · Cited by 58
Oncogenic transformation and experimental models of human cancer
Anna, C. S. (2007) · Frontiers in bioscience · doi:10.2741/2661 · Cited by 63
“Consistent with this view, cells that express markers associated with senescence in cultured cells have been identified in both pre-malignant and malignant lesions (69-72).”
BackgroundAntiviral action of the tumor suppressor ARF
García, M. Á., Collado, M., Muñoz‐Fontela, C., Matheu, A., Marcos-Villar, L., Arroyo, J., Estéban, M., Serrano, M., & Rivas, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601302 · Cited by 62
“Furthermore, activation of Arf by H-rasV12 in vivo during DMBA/TPA-induced papilloma formation in mice (Kelly-Spratt et al, 2004; Collado et al, 2005), a well-established carcinogenic protocol driven by H-ras oncogenic mutation (Quintanilla et al, 1986), resulted in increased levels of eIF2a-P…”
BackgroundSelf-citationTherapy-induced senescence as a component of tumor biology: Evidence from clinical cancer
Saleh, T., Bloukh, S., Hasan, M., & Shboul, S. A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188994 · Cited by 56
Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation
Peyre, M., Stemmer-Rachamimov, A. O., Clermont, E., Quentin, S., El-Taraya, N., Walczak, C., Volk, A., Niwa‐Kawakita, M., Karboul, N., Giovannini, M., et al. (2012) · Oncogene · doi:10.1038/onc.2012.436 · Cited by 60
Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo
Jackson, J. G., Post, S. M., & Lozano, G. (2011) · The Journal of Pathology · doi:10.1002/path.2783 · Cited by 53
Bikkavilli, R. K., Avasarala, S., Scoyk, M. M. V., Arcaroli, J. J., Brzezinski, C. R., Zhang, W., Edwards, M. G., Rathinam, M. K. K., Zhou, T., Tauler, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.2 · Cited by 56
Sin3B Expression Is Required for Cellular Senescence and Is Up-regulated upon Oncogenic Stress
Grandinetti, K. B., Jelinic, P., DiMauro, T., Pellegrino, J., Fernández Rodríguez, R., Finnerty, P. M., Ruoff, R., Bardeesy, N., Logan, S. K., & David, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0537 · Cited by 54
“of local premalignant lesions, namely, metaplastic acini, which have been shown to stain positive for senescence markers (3).”
Selt, F., Buhl, J. L., Hielscher, T., Sahm, F., Capper, D., Korshunov, A., Usta, D., Brabetz, S., Ridinger, J., Ecker, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14004 · Cited by 59
“A generally accepted feature of cells undergoing OIS is their positive staining for SA- β-galactosidase [6, 11].”
BackgroundCancer-Associated Fibroblasts’ Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma
Awaji, M. I., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11030290 · Cited by 56
Ohtani, N. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz055 · Cited by 57
Yang, D., Liu, L., & Zheng, X. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.02.001 · Cited by 57
Bai, P., Xiao, X., Zou, J., Cui, L., Nguyen, T. M. B., Liu, J., Xiao, J., Chang, B., Wu, J., & Wang, H. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.523 · Cited by 55
“To date, evidence suggests that p14 ARF , p15 INK4b and p16 INK4a are widely downregulated in several solid tumors (27), including hepatic (28), breast, urinary bladder, pancreatic and esophageal carcinomas and gliomas (29).”
Sex Differences in Molecular Mechanisms of Cardiovascular Aging
Justina, V. D., Miguez, J. S., Priviero, F. B. M., Sullivan, J. C., Giachini, F. R. C., & Webb, R. C. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.725884 · Cited by 57
“Moreover, changes in cellular structures are visible, in addition to accumulation of several subproducts, including: lipofuscin (Georgakopoulou et al., 2013), embryonic chondrocyte-expressed 1 (DEC1), decoy death receptor 2 (DCR2) (Collado et al., 2005), senescence-associated heterochromatin foci formation (Narita et…”
BackgroundGlucose metabolism and hexosamine pathway regulate oncogene-induced senescence
Gitenay, D., Wiel, C., Lallet-Daher, H., Vindrieux, D., Aubert, S., Payen, L., Simonnet, H., & Bernard, D. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.63 · Cited by 52
Surveillance mechanism linking Bub1 loss to the p53 pathway
Gjoerup, O. V., Wu, J., Chandler-Militello, D., Williams, G. L., Zhao, J., Schaffhausen, B., Jat, P. S., & Roberts, T. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703164104 · Cited by 53
Potassium Channel KCNA1 Modulates Oncogene-Induced Senescence and Transformation
Lallet-Daher, H., Wiel, C., Gitenay, D., Navaratnam, N., Augert, A., Calvé, B. L., Verbeke, S., Carling, D., Aubert, S., Vindrieux, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3690 · Cited by 57
“S1F), and increased levels of a known set of senescence markers including interleukin (IL)-8 (27), Sprouty2 (28), Dec1, and DcR (Supplementary Fig.”
BackgroundA genetic roadmap of pancreatic cancer: still evolving
Notta, F., Hahn, S. A., & Real, F. X. (2017) · Gut · doi:10.1136/gutjnl-2016-313317 · Cited by 61
Rôle de la transition épithélio-mésenchymateuse au cours de la progression tumorale
Puisieux, A. (2009) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32376-3 · Cited by 53
p16INK4a/Ki‐67 co‐expression specifically identifies transformed cells in the head and neck region
Prigge, E., Tóth, C., Dyckhoff, G., Wagner, S., Müller, F., Wittekindt, C., Freier, K., Plinkert, P. K., Hoffmann, J., Vinokurova, S., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29130 · Cited by 59
Nelson, D. M., McBryan, T., Jeyapalan, J. C., Sedivy, J. M., & Adams, P. D. (2014) · AGE · doi:10.1007/s11357-014-9637-0 · Cited by 64
Potential role of senescence in radiation-induced damage of the aged skeleton
Chandra, A., Park, S. S., & Pignolo, R. J. (2018) · Bone · doi:10.1016/j.bone.2018.12.006 · Cited by 54
Cellular senescence in the tumor microenvironment and context‐specific cancer treatment strategies
Yasuda, T., Baba, H., & Ishimoto, T. (2021) · FEBS Journal · doi:10.1111/febs.16231 · Cited by 61
Apoptosis induction by 4-nerolidylcatechol in melanoma cell lines
Brohem, C. A., Sawada, T. C. H., Massaro, R. R., de Almeida, R. L., Rivelli, D. P., Röpke, C. D., da Silva, V. V., de Lima, T. M., Curi, R., Barros, S. B. D. M., et al. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2008.11.004 · Cited by 65
The contrasting roles of lamin B1 in cellular aging and human disease
Dreesen, O., Ong, P. F., Chojnowski, A., & Colman, A. (2013) · Nucleus · doi:10.4161/nucl.25808 · Cited by 58
Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment
Yu, X., Liu, R., Gao, W., Wang, X., & Zhang, Y. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00450-z · Cited by 59
“Preceding studies [92, 93] have shown a positive protective effect of cellular senescence in limiting the malignant progression of tumours.”
BackgroundThe complex interplay between aging and cancer
Trastus, L. A., & di Fagagna, F. D. (2025) · Nature Aging · doi:10.1038/s43587-025-00827-z · Cited by 65
Senescence: the good the bad and the dysfunctional
Pazolli, E., & Stewart, S. A. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.002 · Cited by 60
Metadata
- Authors
- Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., Beach, D., & Serrano, M.
- Affiliations
- Spanish National Cancer Research Centre (ES)
- Imperial College London (GB)
- Consejo Superior de Investigaciones Científicas (ES)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Serrano, Manuel
- ORCID
- Venue
- Nature
- Published
- 2005-08-04
- Volume
- 436
- Issue
- 7051
- Pages
- 642-642
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2067117191
- Cited by
- 1,482
- References
- 7
- Citations by year
- 2026: 31 · 2025: 40 · 2024: 59 · 2023: 58 · 2022: 57 · 2021: 74 · 2020: 87 · 2019: 55 · 2018: 53 · 2017: 68 · 2016: 67 · 2015: 73 · 2014: 76 · 2013: 81 · 2012: 81
- FWCI
- 46.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, oncogene-induced senescence, oncogenic Ras, lymphoma, SUV39H1, histone methyltransferase, epigenetic regulation, melanoma, p53, PTEN mutation, prostate cancer, tumor suppression, cancer diagnosis and prognosis
- MeSH terms
- Adenocarcinoma, Alleles, Animals, beta-Galactosidase, Cell Transformation, Neoplastic, Disease Models, Animal, Heterochromatin, Lung Neoplasms, Mice, Transgenic, Precancerous Conditions, Genes, ras, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Cellular Senescence, Disease Progression, Cyclin-Dependent Kinase Inhibitor p16, Oligonucleotide Array Sequence Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.